C22 Glucosylceramide (d18:1/22:0)
Based on 1 Customer Validation
C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields.
For research use only. We do not sell to patients.
- Purity: 99%
- CAS No.: 119242-44-3
- Formula: C46H89NO8
- Molecular Weight:784.20
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-151240
Galactosylceramide -
HY-154921
Lactosylceramide (bovine buttermilk) -
HY-N7745
Glucosylsphingosine -
HY-W717504
Glucosylceramide, plant -
HY-165035
Glucosylceramide (gaucher's spleen) -
HY-156209
Gb3(d18:1/16:0) -
HY-165892
Dodecanoyl-galactosylceramide -
HY-165855
Octanoyl-galactosylceramide -
HY-165880
Palmitoyl sulfatide -
HY-N11142
Gb3(18:1/18:0) -
HY-158803
C6 Biotin glucosylceramide (d18:1/6:0)
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
In Vitro
C22 Glucosylceramide (d18:1/22:0) is not detected in either parental or Doxorubicin (HY-15142A)-resistant MCF-7 human breast adenocarcinoma cells in this sphingolipidomic analysis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 119242-44-3
-
Appearance Solid
-
Molecular Weight 784.20
-
Formula C46H89NO8
-
Color White to off-white
-
SMILES
CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](NC(CCCCCCCCCCCCCCCCCCCCC)=O)CO[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CO
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (267 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shammout ODA, et al. Comparative sphingolipidomic analysis reveals significant differences between doxorubicin-sensitive and -resistance MCF-7 cells. PLoS One. 2021;16(10):e0258363. Published 2021 Oct 12. [Content Brief]
[2]. Calzada C, et al. Role of circulating sphingolipids in lipid metabolism: Why dietary lipids matter. Front Nutr. 2023;9:1108098. Published 2023 Jan 11. [Content Brief]
[3]. Kwon YJ, et al. Effect of Korean Red Ginseng on Plasma Ceramide Levels in Postmenopausal Women with Hypercholesterolemia: A Pilot Randomized Controlled Trial. Metabolites. 2021;11(7):417. Published 2021 Jun 24. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
C22 Glucosylceramide (d18:1/22:0) Related Classifications
HY-164236 Related Classifications
Powered by Bioz
Keywords
- C22 Glucosylceramide (d18:1/22:0)
- 119242-44-3
- Endogenous Metabolite
- dox-sensitive cancer cells
- cardiovascular event incidence
- bioactive sphingolipid species
- intestine-derived chylomicrons
- overweight participants
- post-menopausal women
- saturated fatty acid-rich meal
- healthy Nordic diet
- glucosylceramide glycosphingolipid
- HDL
- Inhibitor
- inhibitor
- inhibit